TrialThe oncologist2022

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.

Yusuke Chihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.